Luke joined GSK as President, Global Pharmaceuticals in September 2017. He is a member of the GSK Corporate Executive Team and a Board Member for ViiV Healthcare.
At GSK, he is responsible for commercialising a portfolio of medicines and vaccines with annual sales of more than £20 billion and operations in over 100 markets.
His previous role was Executive Vice President of AstraZeneca’s European business and, prior to that, Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs.
Luke joined AstraZeneca from Roche, where he was Regional Vice President Asia Pacific for the Pharmaceuticals Division. Before then, he held roles of increasing seniority at Sanofi-Aventis in Asia and the US. He also co-led the US integration of Sanofi and Aventis. Prior to that, he held general management roles in Thailand and New Zealand, following his entry into the industry in Australia.
He holds a Bachelor of Science degree in Biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.